03 Profile
Hansard to 11 November 2026 · 31,429 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Sector leader · Diabetes
Aaron J. Kowalski
Ph.D., Breakthrough T1D CEO
press citations on 1 topic since 16 Oct 2025 · last quoted 15 Jun 2026
02 Quoted on · 1 of 29 topics
Aaron J. Kowalski: key facts
- Kind of voice
- Sector leader
- Role
- Ph.D., Breakthrough T1D CEO
- Quoted on
- Diabetes
- Tracked press citations
- 2
- Most recently quoted
- 15 Jun 2026
- First quoted
- 16 Oct 2025
04 On the record · press
What Aaron J. Kowalski has said
- breakthrought1d.org1
- fiercepharma.com1
Where Aaron J. Kowalski has been quoted
- 01Sanofi, once on FDA course for speedy approval, gains late expansion for Tzieldfiercepharma.com · 15 Jun 2026
- 02Civica long-acting insulin available on January 1, 2026breakthrought1d.org · 16 Oct 2025
Verbatim
“We now have a novel therapy that targets the autoimmune and progressive nature of stage 3 type 1 diabetes.”
“For people with type 1 diabetes, insulin is a lifesaving drug. Too often, the cost of insulin is a barrier that causes people to make difficult decisions between their medication and other necessities. The availability of Civica's insulin glargine is a significant next step in ensuring that insulin is accessible and affordable for people with type 1 diabetes and all those who need it, regardless of their insurance status.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 13 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.